Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.

Urruticoechea A, Archer CD, Assersohn LA, Gregory RK, Verrill M, Mendes R, Walsh G, Smith IE, Johnston SR.

Br J Cancer. 2005 Feb 14;92(3):475-9.

2.

Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer.

Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S, Gui G, Sacks N, Ebbs SR, Allum W, Nasiri N, Dowsett M.

Br J Cancer. 2003 Sep 15;89(6):1035-41.

3.

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.

Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon A, Koh DM, Gill K, Uzzell M, Prior Y, Catovsky D.

Br J Haematol. 2003 Mar;120(6):970-7.

PMID:
12648066
4.

A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy.

Assersohn L, Souberbielle BE, O'Brien ME, Archer CD, Mendes R, Bass R, Bromelow KV, Palmer RD, Bouilloux E, Kennard DA, Smith IE.

Clin Oncol (R Coll Radiol). 2002 Feb;14(1):23-7.

PMID:
11899903
5.

Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer.

Archer CD, Lowdell C, Sinnett HD, English J, Khan S, Coombes RC.

Eur J Cancer. 1998 May;34(6):816-9.

PMID:
9797691
10.

Supplemental Content

Loading ...
Support Center